Hospital Authority implements fees and charges reform rationalising healthcare services and enhancing patient protection

Source: Hong Kong Government special administrative region

The following is issued on behalf of the Hospital Authority:

The Hospital Authority (HA) announced today (March 25) the completion of public healthcare fees and charges reform review and submission of policy recommendations to the Health Bureau. The proposals adhere to the principle that no person should be denied, through lack of means, from obtaining adequate medical treatment, aiming to strengthen healthcare protection, rationalise public hospital service subsidies, reduce wastage and misuse, and enhance the sustainability of the public healthcare system by reforming the public healthcare subsidy framework.
 
The Chairman of the HA, Mr Henry Fan, said, “We sincerely thank the Health Bureau for leading the HA in conducting this fees and charges reform review. Through this reform, the HA can promote the development of Hong Kong’s public healthcare services. We believe that once the fees and charges reform measures are fully implemented, the current service imbalances in public hospitals can be gradually straightened out and the protection for patients, especially those with critical illnesses or emergency conditions, can be enhanced. This will enable sustainable development of public healthcare services to cope with the various challenges posed by Hong Kong’s ageing population.”
 
Currently, the government provides a high degree of subsidy for HA services, with a subsidy rate as high as 97.6 per cent, with the subsidy amount for some public hospital services even reaching 100 per cent. Beyond facing challenges from an ageing population creating excess demand, Hong Kong’s public healthcare system experiences systemic imbalances, subsidy misallocations, and service waste. To ensure the sustainability of the public healthcare system, the HA initiated a review to reform public healthcare fees and charges last year, based on relevant principles including public affordability, optimal service utilisation, cost sharing, subsidy prioritisation, support for the underprivileged and public acceptance. The review covers the following areas:
 
Reforming the susidisation structure
 

  • systematically reforming the subsidisation structure to determine government subsidy levels and citizen copayment ratios across different public healthcare services, rationalising relative demand across inpatient, emergency, and outpatient services, to provide patients with appropriate medical services;

Reducing wastage and misuse
 

  • introducing copayment models for non-emergency diagnostic radiology and pathology examination services, adjusting standard drug fees and quantities to change the public’s healthcare-seeking behavior and ensure limited medical resources can be precisely allocated to patients needed;

Strengthening healthcare protection
 

  • enhancing the medical fee waiving mechanism, relaxing the income and asset limit to significantly strengthen support for low-income families and underprivileged groups;
  • introducing a cap on annual spending of $10,000 for public healthcare services (excluding self-financed items) to better care for critically ill patients;
  • accelerating the introduction of more effective innovative drugs and devices and relaxing the eligibility criteria of means test for the safety net applications, so that more critically ill patients can receive subsidy for self-financed drugs and devices.

 
The Chief Executive of the HA, Dr Tony Ko, said, “The HA will fully implement the reform. Under the reform, subsidy ratios will vary by service type of public hospitals, depending on the nature of the service. After the reform, the public copayment ratio will remain affordable. Through the enhanced medical fee waiving mechanism, relaxed eligibility criteria of means test for Samaritan Fund safety net applications, and a cap on annual spending on inpatient and outpatient fees, the HA will continue to ensure that no one will be denied adequate medical care due to lack of means and will strengthen the protection of the public, not only taking care of the underprivileged groups, but also preventing middle income people from impoverishment due to illness.”
 
After the implementation of measures such as enhancing medical fee waiving mechanism, relaxing eligibility criteria of means test for Samaritan Fund safety net applications, and establishing a cap on annual spending on inpatient and outpatient fees, over 1.4 million people are expected to be eligible for protection. The HA pledges that all additional revenue generated from fees and charges adjustments will be entirely utilised to medical services, particularly supporting those with critical conditions like cancer or rare diseases, waiving or reducing self-financed medications and devices or medical supplies fees. The HA can also accelerate the introduction of more effective new medications and devices to improve treatment outcomes.
 
The detailed fee schedule will take effect in January 2026 (see Annex). Details of enhanced protection measures, include enhancing medical fee waiving mechanism, introducing an annual fee cap on inpatients and outpatients of $10,000, and relaxing eligibility criteria of means test for Samaritan Fund safety net application, are provided in the appendix. The HA’s last fee adjustment was in 2017.
 
Mr Fan stated that Hong Kong’s public hospitals remain among the world’s most efficient healthcare providers. The HA will continue promoting reforms to improve the service level of public hospitals, and ensure limited medical resources can be used for patients most in need. Once the public healthcare fees and charges reform achieves its target within five years, Hong Kong’s public healthcare system will take a major step forward. The HA will also fully cooperate with other government healthcare reform measures to continue providing high-quality and sustainable medical services with appropriate healthcare protection for Hong Kong citizens.

Annex
 
Public healthcare fees and charges reform
 

Service Current fee Fees effective from January 1, 2026
Inpatient
(Acute bed)
Admission fee $75 To cancel
Maintenance fee (per day) $120 $300
Inpatient
(convalescent / rehabilitation, infirmary and psychiatric beds)
Maintenance fee (per day)
$100 $200
Day procedure and treatment Admission fee $75 To cancel
Maintenance fee (per day) $120 $250
Day hospital
(Geriatric, rehabilitation) 
$60 / $55 $100
Community nursing service,
Community allied health service
$80 $100
Community psychiatric nursing service Free Free
Psychiatric day hospital $60 Free
Accident and emergency $180 $400
(Fee exempted for Category I, II)
Specialist outpatient clinic (SOPC) (Include allied health clinic) 1st attendance $135 $250
Subsequent $80
Drug $15 per unit,
16 weeks maximum
$20 per unit,
up to 4 weeks
Pathology testing service
(applicable for SOPC)
Basic No additional charges Free
Intermediate $50
Advanced $200
Non-emergency radiology imaging service Basic No additional charges Free
Intermediate $250
Advanced $500
Family medicine outpatient service Consultation Family medicine outpatient service
 
$135 for the 1st attendance
 
$80 per
subsequent attendance
$150
$50 for general outpatient
Drug
 
Family medicine outpatient service
 
$15 per unit,
16 weeks maximum
$5 per unit,
up to 4 weeks
No additional charge for general outpatient

Declare wheat stock position w.e.f. 1st April, 2025 and then on, every Friday: Centre

Source: Government of India

Posted On: 25 MAR 2025 8:10PM by PIB Delhi

In order to manage the overall food security and to prevent unscrupulous speculation, the Government of India has decided that Traders/Wholesalers, Retailers, Big Chain Retailers and Processors in all States and Union Territories have to declare their Stock position of wheat on the portal (https://evegoils.nic.in/wsp/login) w.e.f. 01.04.2025 and then, on every Friday till further orders. All the respective legal entities to ensure that stock are regularly and correctly disclosed on the portal.
 
Wheat Stock Limit is expiring on 31.03.2025 for all categories of entities in States and UTs. Thereafter, the entities have to disclose the wheat stock on portal. Any entity which is not registered on the Portal, may register themselves and start disclosing the wheat stock on every Friday.
 
The Department of Food and Public Distribution is maintaining a close watch over the stock position of wheat to prevent speculation, control prices and ensure easy availability in the country

****

Abhishek Dayal/Nihi Sharma

(Release ID: 2115042) Visitor Counter : 13

CCI approves acquisition of Athaang Devanahalli Tollway Private Limited, Athaang Jammu Udhampur Highway Private Limited and Quazigund Expressway Private Limited by Cube Highways Trust and Cube Highways and Infrastructure V Pte. Ltd.

Source: Government of India

Posted On: 25 MAR 2025 7:47PM by PIB Delhi

The Competition Commission of India has approved acquisition of Athaang Devanahalli Tollway Private Limited, Athaang Jammu Udhampur Highway Private Limited and Quazigund Expressway Private Limited by Cube Highways Trust and Cube Highways and Infrastructure V Pte. Ltd.

The Proposed Combination envisages:

  1. acquisition of 100% shareholding of Athaang Devanahalli Tollway Private Limited (ADTPL) by Cube Highways and Infrastructure V Pte. Ltd. (Cube V); and
  2. acquisition of 100% shareholding of (i) Athaang Jammu Udhampur Highway Private Limited (AJUHPL), and (ii) Quazigund Expressway Private Limited (QEPL) by Cube Highways Trust (Cube Trust).

(Hereinafter ADTPL, AJUHPL and QEPL are collectively referred to as the ‘Targets’)

The Cube Trust is an infrastructure investment trust registered with the Securities and Exchange Board of India (SEBI) under the SEBI (Infrastructure Investment Trusts) Regulations, 2014 (as amended). The road assets/ SPVs of Cube Trust are engaged, inter alia, in the operation and maintenance (O&M) of various road and highway projects in India.

Cube V is registered as a foreign portfolio investor with the SEBI and acquires, operates and manages road assets in India.

The Targets have been incorporated in India as special purpose vehicles and are engaged in the business of operating (through governmental concessions) roads and highways in India.

Detailed order of the Commission will follow.

*****

 NB/AD

(Release ID: 2115027) Visitor Counter : 97

CCI approves the proposed combination involving, inter alia, Maple Infrastructure Trust (MIT); CDPQ Infrastructures Asia III Inc. (CDPQ Asia); Maple Highways Pte. Ltd.; 360 ONE Private Equity Fund and certain road assets of the Ashoka Buildcon group

Source: Government of India

Posted On: 25 MAR 2025 7:46PM by PIB Delhi

The Competition Commission of India has approved the proposed combination involving, inter alia, Maple Infrastructure Trust (MIT); CDPQ Infrastructures Asia III Inc. (CDPQ Asia); Maple Highways Pte. Ltd.; 360 ONE Private Equity Fund and certain road assets of the Ashoka Buildcon group.

The Proposed Combination involves the acquisition by MIT, acting through Maple Infra Invit Investment Manager Private Limited (Maple IM) of Ashoka Dhankuni Kharagpur Tollway Limited (ADKTL); Ashoka Sambalpur Baragarh Tollway Limited (ASBTL); Ashoka Belgaum Dharwad Tollway Limited (ABDTL); Ashoka Highways (Bhandara) Limited (AHBL); and Ashoka Highways (Durg) Limited (AHDL) (Proposed SPV Acquisitions) and certain inter-connected transactions.

MIT is a private trust settled under the Indian Trusts Act, 1882, and was registered as an infrastructure investment trust under the Securities and Exchange Board of India (Infrastructure Investment Trusts) Regulations, 2014, on 24th February 2020. MIT is, through its special purpose vehicles, engaged in the business of owning and operating road assets in India. Maple IM is the investment manager of MIT.

CPDQ Asia is a wholly owned subsidiary of Caisse de dépôt et de placement du Québec (CDPQ). CDPQ is a global investment group that manages the funds of its depositors, primarily comprised of public and para-public pension and insurance plans from Québec.

Maple Sponsor is the sponsor of MIT for purposes of the Securities and Exchange Board of India (Infrastructure Investment Trusts) Regulations, 2014.

360 ONE Private Equity Fund is registered with the SEBI as a Category II Alternative Investment Fund and is established for the purpose of investing in various sectors in India and worldwide. The 360 ONE Private Equity Fund is managed by its investment manager, 360 ONE Alternates Asset Management Limited.

ADKTL, ASBTL, ABDTL, AHBL and AHDL are engaged by the National Highway Authority of India Limited (NHAI) to provide infrastructure concession services.

Detailed order of the Commission will follow.

 

*****

NB/AD

(Release ID: 2115025) Visitor Counter : 73

Competition Commission of India (CCI) approves the acquisition of 100% equity shareholding in 11 road special purpose vehicles owned by Ashoka Concessions Limited and Ashoka Buildcon Limited by Epic Concesiones 2 Private Limited

Source: Government of India

Posted On: 25 MAR 2025 7:44PM by PIB Delhi

The Competition Commission of India has approved the acquisition of 100% equity shareholding in 11 road special purpose vehicles owned by Ashoka Concessions Limited and Ashoka Buildcon Limited by Epic Concesiones 2 Private Limited.

The Proposed Combination envisages acquisition of 100% equity shareholding by Epic Concesiones 2 Private Limited (EC2PL) in road 11 special purpose vehicles (Target SPVs) owned by Ashoka Concessions Limited (ACL) and Ashoka Buildcon Limited (ABL) (Proposed Equity Transaction).

EC2PL is a private limited company engaged in owning and operating infrastructure projects. It is owned by Infrastructure Yield Plus II (IYP II) & Infrastructure Yield Plus IIA (IYP IIA) (collectively IYP), which are both schemes of the Infrastructure Yield Trust, an irrevocable and determinate contributory investment trust under the Indian Trusts Act, 1882 and registered with the SEBI as a Category I – Infrastructure Alternative Investment Fund, under the SEBI (Alternative Investment Funds) Regulations, 2012. The investment manager of IYP II and IYP IIA is EAAA India Alternatives Limited (EIAL) which is an indirect wholly-owned subsidiary of EFSL, the parent entity of EC2PL.

The Target SPVs are eleven road SPVs have been incorporated in India and are engaged in the business of operating (through governmental concessions) roads and highways in India.

Detailed order of the Commission will follow.

*****

NB/AD

(Release ID: 2115024) Visitor Counter : 93

Medium Term and Long Term Government Deposit (MLTGD) components of Gold Monetisation Scheme (GMS) discontinued w.e.f. 26th March, 2025, based on performance of GMS and evolving market conditions

Source: Government of India

Posted On: 25 MAR 2025 7:24PM by PIB Delhi

The Gold Monetisation Scheme (GMS) was announced on 15th September, 2015 with the objective to reduce country’s reliance on the import of gold in the long run and mobilise gold held by households and institutions in the country to facilitate its use for productive purposes.

The GMS comprised of 3 components:

  1. Short Term Bank Deposit (1-3 years)
  2. Medium Term Government Deposit (5-7 years), and
  3. Long-Term Government Deposit (12 – 15 years)

Based on the examination of the performance of the Gold Monetisation Scheme (GMS) and evolving market conditions, it has been decided to discontinue the Medium Term and Long Term Government Deposit (MLTGD) components of the GMS w.e.f. March 26, 2025.

Accordingly, any gold deposits tendered at the designated Collection and Purity Testing Centre (CPTC) or GMS Mobilisation, Collection & Testing Agent (GMCTA) or the designated bank branches under the said components of GMS shall not be accepted with effect from March 26, 2025. However, the existing deposits under MLTGD shall continue till redemption as per extant guidelines of GMS issued vide Reserve Bank Master Direction No. DBR.IBD.No.45/23.67.003/2015-16 dated October 22, 2015 (as updated).

Further, the Short-Term Bank Deposits (STBD) offered by the banks under GMS shall continue at the discretion of the individual banks based on the commercial viability as assessed by them. The detailed guidelines of Reserve Bank in this regard shall follow.

****

NB/KMN

(Release ID: 2115009) Visitor Counter : 187

Union Public Service Commission (Upsc) announces Final Results of Combined Defence Services Examination (II), 2024

Source: Government of India

Posted On: 25 MAR 2025 7:14PM by PIB Delhi

The following are the lists, in order of merit of 349 (223 + 89 + 37) candidates who have qualified on the basis of the results of the Combined Defence Services Examination (II), 2024 conducted by the Union Public Service Commission in  September, 2024 and SSB interviews held by the Services Selection Board of the Ministry of Defence for admission to the 159th (DE) Course of Indian Military Academy, Dehradun; Indian Naval Academy, Ezhimala, Kerala and Air Force Academy, Hyderabad (Pre-Flying) Training Course i.e. No. 218 F(P) Course.

2.         There are some common candidates in the three lists for various courses.

3.         The number of vacancies, as intimated by the Government is 100 for Indian Military Academy [including 13 vacancies reserved for NCC ‘C’ Certificates (Army Wing) holders], 32 for Indian Naval Academy, Ezhimala, Kerala Executive Branch (General Service)/Hydro[including 06 vacancies for NCC ‘C’ Certificate (Naval Wing) holders] and 32 for Air Force Academy, Hyderabad [03 vacancies are reserved for NCC ’C’ Certificate (Air Wing) holders through NCC Spl. Entry].

4.         The Commission had recommended 2534, 900, and 613 as qualified in the written test for admission to the Indian Military Academy, Indian Naval Academy and Air Force Academy, respectively.  The number of candidates finally qualified are those after SSB test conducted by Army Head Quarters.

5.         The results of Medical examination have not been taken into account in preparing these lists.

6.         Verification of date of birth and educational qualifications of these candidates is still under process by the Army Headquarters.  The candidature of all these candidates is, therefore, Provisional on this score.  Candidates are requested to forward their certificates, in original, in support of Date of Birth/Educational qualification etc. claimed by them, along with Photostat attested copies thereof to Army Headquarters /Naval Headquarters /Air Headquarters, as per their first choice.

7.         In case, there is any change of address, the candidates are advised to promptly intimate directly to the Army Headquarters /Naval Headquarters /Air Headquarters.

8.         These results will also be available on the UPSC website at http://www.upsc.gov.in However, marks of the candidates will be available on the website after declaration of final result of Officers’ Training Academy (OTA) Course for Combined Defence Services Examination (II), 2024.

9.         For any further information, the candidates may contact Facilitation Counter near Gate ‘C’ of the Commission’s Office, either in person or on telephone Nos. 011-23385271/011-23381125/011-23098543 between 10:00 hours and 17:00 hours on any working day.

Click here for see the result

*****

NKR/PSM

(Release ID: 2115002) Visitor Counter : 146

Read this release in: Tamil

Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, 15,057 Jan Aushadhi Kendras (JAKs) have been opened till 28.2.2025 across the country

Source: Government of India

Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, 15,057 Jan Aushadhi Kendras (JAKs) have been opened till 28.2.2025 across the country

For smooth supply and product availability at JAKs, an end-to-end IT-enabled supply chain system has been established; It comprises one central warehouse at Gurugram and four regional warehouses at Bengaluru, Guwahati, Chennai and Surat

Posted On: 25 MAR 2025 7:02PM by PIB Delhi

Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme, a total of 15,057 Jan Aushadhi Kendras (JAKs) have been opened till 28.2.2025 across the country, the State- and Union-territory-wise numbers of which are at Annexure.

Lack of availability of medicines to JAKs is not a systemic issue. For smooth supply and product availability at JAKs, an end-to-end IT-enabled supply chain system has been established. It comprises one central warehouse at Gurugram and four regional warehouses at Bengaluru, Guwahati, Chennai and Surat. Further, 36 distributors have been appointed across the country to strengthen the supply chain system. Availability of 400 fast-moving products is monitored regularly to ensure their availability. Further, a minimum stocking mandate has been implemented for 200 medicines consisting of the 100 top-selling medicines in the scheme product basket and 100 fast-selling medicines in the market. Under the stocking mandate, the Jan Aushadhi Kendra owners become eligible for claiming incentive based on stocks of the said 200 medicines maintained by them. Thus, supply of medicines to JAKs is ensured through the system of warehouses and distributors and monitoring system and incentives are in place to encourage JAKs to stock the products that are more in demand. JAKs being run on an entrepreneurship model, the actual stocking of products is done by entrepreneurs based on demand for the same.

To safeguard against complaints about the quality of medicines sold from JAKs, stringent measures as specified below are in place to ensure that the medicines supplied through Jan Aushadhi Kendras meet standards:

  1. Medicines are procured only from suppliers certified for World Health Organization – Good Manufacturing Practices (WHO-GMP).

  2. Each batch of drugs supplied under the scheme is tested at laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and only after passing quality tests, medicines are dispatched to Jan Aushadhi Kendras.

  3. Quality audit of the facilities of vendors is routinely done by the Pharmaceuticals and Medical Devices Bureau of India.

Jan Aushadhi Kendras (JAKs) opened till 28.2.2025

S. No.

State / Union Territory

JAKs opened

1

Andaman and Nicobar Islands

9

2

Andhra Pradesh

275

3

Arunachal Pradesh

34

4

Assam

170

5

Bihar

812

6

Chandigarh

11

7

Chhattisgarh

278

8

Delhi

492

9

Goa

15

10

Gujarat

760

11

Haryana

408

12

Himachal Pradesh

71

13

Jammu and Kashmir

318

14

Jharkhand

148

15

Karnataka

1,425

16

Kerala

1,528

17

Ladakh

2

18

Lakshadweep

1

19

Madhya Pradesh

545

20

Maharashtra

708

21

Manipur

54

22

Meghalaya

25

23

Mizoram

15

24

Nagaland

22

25

Odisha

682

26

Puducherry

33

27

Punjab

489

28

Rajasthan

486

29

Sikkim

11

30

Tamil Nadu

1,363

31

Telangana

199

32

Dadra and Nagar Haveli and Daman and Diu

39

33

Tripura

28

34

Uttar Pradesh

2,658

35

Uttarakhand

313

36

West Bengal

630

Total

15,057

 

This information was given by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Rajya Sabha in written reply to a question today.

 

*****

MV/AKS

(Release ID: 2114994) Visitor Counter : 154

New Investment Policy (NIP) to facilitate fresh investment and making India Self-Sufficient in the urea sector

Source: Government of India

New Investment Policy (NIP) to facilitate fresh investment and making India Self-Sufficient in the urea sector

Total 6 new urea units have been set up under NIP-2012 including 4 Urea units set up through Joint Venture Companies (JVC) of nominated PSUs and 2 Urea units set up by the private companies

Posted On: 25 MAR 2025 7:01PM by PIB Delhi

The Government had announced New Investment Policy (NIP) – 2012 on 2nd January, 2013 and its amendment on 7th October, 2014 to facilitate fresh investment in the urea sector and to make India self-sufficient in the urea sector. Total 6 new urea units have been set up under NIP-2012 which includes 4 Urea units set up through Joint Venture Companies (JVC) of nominated PSUs and 2 Urea units set up by the private companies. The units set up through JVC are Ramagundam Urea unit of Ramagundam Fertilizers and Chemicals Ltd (RFCL) in Telangana and 3 Urea units namely Gorakhpur, Sindri and Barauni of Hindustan Urvarak & Rasayan Limited (HURL) in Uttar Pradesh, Jharkhand and Bihar, respectively. The units set up by private companies are Panagarh Urea unit of Matix Fertilizers and Chemicals Ltd. (Matix) in West Bengal; and Gadepan-III Urea unit of Chambal Fertilizers and Chemicals Ltd. (CFCL) in Rajasthan. Each of these units has installed capacity of 12.7 Lakh Metric Tonne per annum (LMTPA). These units are highly energy efficient as they are based on latest technology.  Therefore, these units have together added urea production of 76.2 LMTPA thereby total production urea production capacity (RAC) has increased from 207.54 LMTPA during 2014-15 to 283.74 LMTPA in 2023-24.

The Government has implemented Nutrient Based Subsidy Policy w.e.f. 01.04.2010 for Phosphatic and Potassic (P&K) Fertilizers. Under the policy, a fixed amount of subsidy, decided on annual/bi-annual basis, is provided on notified P&K fertilizers depending on their nutrient content. The P&K sector is decontrolled, fertilizer companies are allowed to fix MRP at reasonable levels.The fertilizer companies manufacture/import fertilizers and do investment as per the market dynamics.

This information was given by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Rajya Sabha in written reply to a question today.

*****

MV/AKS

(Release ID: 2114993) Visitor Counter : 147

Scheme for Promotion of Research and Innovation in the Pharma Medtech sector to promote research and development (R&D) including in the areas of artificial intelligence (AI) and machine learning

Source: Government of India

Scheme for Promotion of Research and Innovation in the Pharma Medtech sector to promote research and development (R&D) including in the areas of artificial intelligence (AI) and machine learning

National Institutes of Pharmaceutical Education and Research (NIPER) provide training in AI-based tools to build human resource capacities in these areas for the pharmaceutical sector

Posted On: 25 MAR 2025 6:58PM by PIB Delhi

The Department of Pharmaceuticals (DoP) has taken steps to promote research and development (R&D) in the sector, including in the areas of artificial intelligence (AI) and machine learning, in the pharmaceutical sector through the Scheme for Promotion of Research and Innovation in the Pharma Medtech sector. Further, the National Institutes of Pharmaceutical Education and Research (NIPER) under the aegis of DoP have introduced topics related to AI and block chain technology in their courses and they provide training to students in AI-based tools to build human resource capacities in these areas for the pharmaceutical sector. In addition, the Department of Biotechnology also supports AI-based research activities in the biotech sector, particularly in the healthcare and agriculture areas, in order to leverage emerging technologies for these sectors. Further, the Pharmaceuticals and Medical Devices Bureau of India under the Department of Pharmaceuticals, with the assistance of the Centre for Development of Advanced Computing, has undertaken a pilot project to evaluate the feasibility of a block-chain-based track-and-trace system for Pradhan Mantri Bhartiya Janaushadhi Pariyojana.

This information was given by the Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel in Rajya Sabha in written reply to a question today.

*****

 

MV/AKS

(Release ID: 2114991) Visitor Counter : 146